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Abstract
Introduction Osteoclasts play a key role in the pathogenesis of
bone erosion and systemic bone mass loss during rheumatoid
arthritis (RA). In this study, we aimed to determine the effect of
methotrexate (MTX) and zoledronic acid (ZA), used alone or in
combination, on osteoclast-mediated bone erosions and
systemic bone mass loss in a rat model of collagen induced
arthritis (CIA). We hypothesized that MTX and ZA could have an
additive effect to prevent both bone erosion and systemic bone
loss.
Methods Arthritis was induced in 64 female Sprague-Dawley
rats. After the clinical onset of CIA, rats were assigned to
treatment with MTX (1 mg/kg/week), ZA (100 μg/kg twice
weekly), both treatments at the same regimens, or vehicle.
Arthritis score and paw thickness were recorded twice weekly.
The rats were sacrificed on D28 and hind paws were removed
for radiographic, histological and immunohistochemical
analysis. The effects of treatments on osteoclastogenesis were
determined by Tartrate resistant acid phosphatase (TRAP)
staining. Micro-CT of the tibia was carried out for
histomorphometric analysis. Bone mass density was evaluated
by densitometry.
Results MTX significantly decreased the severity of CIA,
whereas ZA slightly exacerbated it. When these two drugs were
used in combination, MTX prevented the pro-inflammatory effect
of ZA. The combination of ZA with MTX was more effective than
MTX alone for reducing structural joint damage with a dramatic
decrease of osteoclasts' number in the eroded joints. However,
MTX alone also significantly reduced the number of osteoclasts
and the number of CD68+ mononuclear cells. ZA alone, or ZA
with MTX, significantly increased the systemic bone mass
density measured by densitometry and bone volume on
histomorphometric analysis.
Conclusions A combination of MTX and ZA prevented both
bone erosion and systemic bone loss in a rat model of arthritis.
Both treatments independently decreased the number of
osteoclasts in the eroded joint. However, while MTX probably
acts mainly through a decrease of inflammation, ZA has a direct
effect on osteoclasts, allowing a dramatic down-regulation of
these cells in inflamed joints. These two different mechanisms of
action provide support for the use of a combination of these two
drugs to improve the prevention of structural joint damage in RA.
Introduction
Rheumatoid arthritis (RA) is characterized by a chronic inflam-
mation of synovium, leading to progressive joint destruction.
Erosions of the periarticular bone, the most specific hallmark
of the disease, produce deformation, laxity, and functional dis-
ability. Local and systemic inflammation also favors general-
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ized osteopenia or osteoporosis. Osteoclasts are considered
as the principal cell type responsible for focal bone resorption
in RA [1,2]. Gravallese and colleagues first described tartrate
resistant acid phosphatase (TRAP) positive multinucleated
cells in resorption lacunae at the bone-pannus interface in
patients with juvenile arthritis [3]. Several lines of evidence
have since confirmed the role of osteoclasts in bone destruc-
tion during RA. Osteopetrotic mouse models with a genetic
block in osteoclast formation, such as receptor activator of
nuclear factor kappa B-ligand (RANK-L) -/- mice, develop
arthritis but display no bone erosion [4]. Treatment with a chi-
meric osteoprotegerin fusion protein, which inhibits osteoclast
differentiation, efficiently prevents bone erosion in the rat col-
lagen-induced arthritis model [5]. The origin of osteoclasts in
arthritic joints remains unclear. These cells may differentiate
from monocytic precursor cells that home to the inflamed syn-
ovial tissue or from bone marrow precursors, under the influ-
ence of cytokines, such as RANK-L or TNF-alpha, generated
in the synovium of patients with RA [6]. Transdifferentiation
from other subsets of immune cells, including dendritic cells,
has also been proposed [7].
Osteoporosis in RA patients may be attributed to various risk
factors, including primary osteoporosis risk factors, immobili-
zation, use of corticosteroids, and systemic inflammation.
Osteoclasts also play a crucial role in the development of gen-
eralized osteoporosis, mediated through the osteoprotegerin/
RANK/RANK-L signaling system [8]. Recent studies have
demonstrated that targeting RANK-mediated osteoclastogen-
esis with denosumab prevents systemic bone loss in RA
patients [9].
The prevention of joint damage and systemic bone mass loss
is a key goal of treatment for RA. Zoledronic acid (ZA), a nitro-
gen-containing third-generation bisphosphonate, is widely
used to treat metastatic bone disease and has recently been
used for osteoporosis [10,11]. ZA, like other bisphospho-
nates, has a direct effect on mature osteoclasts, inducing their
apoptosis and inhibiting their activity. ZA has been shown to
be effective for the prevention of osteoporosis, but its ability to
confer local joint protection remains a matter of debate.
Indeed, although ZA has been shown to prevent bone erosion
in animal models of arthritis [12,13], only one study in humans
has reported a significant decrease in bone erosion in patients
in the early stages of RA treated with ZA [14].
Methotrexate (MTX) is the first-line therapy for RA. It is effec-
tive against inflammatory symptoms but also in the prevention
or reduction of bone erosions [15]. It is also required to
achieve maximal suppression of bone destruction during the
treatment of RA patients with TNF-alpha-inhibitor [16].
Although TNF inhibitors have clearly improved the prevention
of joint destruction, double-blind comparisons of MTX and
TNF inhibitors, used alone and in combination, have shown the
structural benefits of MTX treatment to be very similar to the
effect of TNF inhibitors alone [17]. The underlying mechanism
of the strong structure-modifying effect of MTX has not been
studied in detail. MTX may inhibit osteoclastogenesis indi-
rectly, by decreasing the production of osteoclastogenic
cytokines, such as TNF-α and IL-6, or by reducing RANK-L
secretion by synovial fibroblasts or macrophages [18]. Alter-
natively, low-dose MTX may inhibit osteoclastogenesis
directly, although only high doses of MTX have been reported
to have negative effects on bone, probably through the inhibi-
tion of osteoblasts [19].
Very few studies have investigated the effect of MTX in vivo,
even for osteoclastogenesis. We therefore sought to deter-
mine the effects of MTX and ZA, used alone or in combination,
on bone erosions and systemic bone loss in the rat collagen-
induced arthritis model, focusing on the effect of these treat-
ments on osteoclasts. In addition to clinical and radiological
evaluations, we also investigated the effect of MTX and ZA on
the number of osteoclasts in the eroded joint. We also studied
CD68+ cells, because monocytes may be modulated by MTX
therapy and a subset of these cells a source of osteoclast pre-
cursors. Systemic bone mass was analyzed by densitometry
and histomorphometry was investigated by micro-computed
tomography (CT). We hypothesized that MTX and ZA would
have additive effects, decreasing bone erosion and bone mass
loss.
Materials and methods
Animals and induction of collagen-induced arthritis
We used eight-week-old female Sprague-Dawley rats (IFFA-
CREDO, l'Arbresles, France) as a model of arthritis. All ani-
mals were fed standard rodent chow and supplied with drink-
ing water ad libitum. Animals were allowed to acclimatize to
the conditions for one week before the experiments. Arthritis
was induced in all the rats as follows: lyophilized native bovine
type II collagen (Sigma, Lyon, France) was dissolved at a con-
centration of 2 mg/ml in 0.1 M acetic acid. The solution was
incubated overnight at 4°C, and 0.3 ml of this solution in a 1:1
emulsion with complete Freund's adjuvant was injected intra-
dermally into the base of the tail on days 0 and 14. Arthritis
developed 15 to 17 days after the first injection. All experimen-
tal procedures conformed to institutional guidelines, were
approved by the institutional review board and were carried
out under the supervision of accredited investigators (FR, DH).
Treatments
Two independent experiments were performed. In each exper-
iment, 32 rats were assigned to four groups of eight rats each
and treated with MTX (Sigma, Lyon, France), ZA (Novartis
Pharma, Bâle, Switzerland), MTX + ZA or placebo. Group 1
was treated with MTX dissolved in PBS at a dose of 1 mg/kg/
week, administered intraperitoneally in a single installment.
Group 2 received 100 μg/kg ZA, administered subcutane-
ously, twice weekly. Group 3 received both treatments at the
same doses as used for groups 1 and 2. Group 4 was used asAvailable online http://arthritis-research.com/content/11/6/R185
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the positive control and treated with PBS. All the treatments
were used at doses previously described in the literature as
being effective [12,13,20]. Treatments were started at the
onset of arthritis, 15 days after the first injection.
Clinical assessment of arthritis
Clinical signs of arthritis were assessed by investigators blind
to the treatment group, twice weekly, as previously described
[1]. Joint swelling was assessed with a semi-quantitative clini-
cal score running from 0 to 4 (0 = no swelling, 1 = weak swell-
ing and/or erythema, 2 = mild swelling, 3 = moderate swelling,
4 = severe swelling of the toes and ankle). This system yielded
a total weekly score between 0 and 8 for each animal (sum of
two assessments per week, each of which gave a score of 0
to 4). Hind footpad width was also measured with calipers at
baseline, twice weekly. The body weight of the rats was mon-
itored with a balance with a precision of 0.1 g.
Radiological examinations
At the end of the experiment, rats were sacrificed using carbon
dioxide asphyxiation and the hind paws were radiographed
with a digital mammography system (Planmed, Helsinki, Fin-
land) used to provide high-resolution images. The ankle and
tarsus joints were graded for erosions (0 to 3) and soft-tissue
swelling (0 to 3), with scores of 1 and 3 corresponding to no
involvement and to extensive involvement, respectively [21].
Two observers blind to treatment assignment and with signifi-
cant experience in reading and rating radiographs for patients
with RA evaluated the radiographs. A total radiological score
was obtained by summing the scores awarded to the two hind
paws by both observers, giving a maximum score of 12 per rat
for each radiological parameter.
Conventional histology, immunohistochemistry and 
TRAP staining
After radiological examination, the hind paws were removed,
fixed by incubation in 10% buffered formaldehyde for 48 hours
and decalcified by incubation in 4.1% EDTA, 0.2% Parafor-
maldehyde (PFA) in PBS at 4°C, with the decalcifying solution
changed twice weekly, for four weeks. The paws were embed-
ded in paraffin, serial sections (5 μm) were cut and mounted
on glass slides and stained with H&E. Histological analysis
(three sections per rat) were carried out for the tibiotarsal and
all intertarsal joints. For standardization, tibial, tarsal and meta-
tarsal bones had to be present in the same section for analysis.
Inflammation was quantified on H&E-stained sections, using a
semi-quantitative score (scale of 0 to 3) at low magnification
(×10): 0 = normal, 1 = mild inflammation, 2 = moderate inflam-
mation, 3 = marked inflammation [22]. Bone erosion was
scored at low (× 10) and high (× 40) magnification, on the fol-
lowing scale: 0 = none, 1 = mild, 2 = moderate and 3 = severe
erosions. For TRAP staining, sections were incubated for one
hour in 1 mg/ml naphthol AS-TR phosphate (N-(4-Chloro-2-
methylphenyl)-3-(phosphonooxy)naphthalene-2-carboxam-
ide), 60 nmol/l NN-dimethylformamide, 100 nmol/l sodium tar-
trate, and 1 mg/ml Fast red TR salt solution (all from Sigma,
Lyon, France) The number of osteoclasts (three or more
TRAP-positive cells) within the eroded area was determined at
high magnification (× 100), with a commercial image analysis
program (Axiovision 4.7, Zeiss, Le Pecq, France). The results
are expressed as the total number of osteoclasts per slide.
We investigated the effect of the treatments on monocyte infil-
tration, by carrying out immunohistochemical analyses with an
automatic tissue stainer (Autostainer 360, Lab vision, Fremont,
CA, USA), using a monoclonal mouse anti-rat CD68 antibody
(Clone ED-1, 1:100 dilution, abd Serotec, Cergy Saint-Chris-
tophe, France). Endogenous peroxidase activity was blocked
by incubation for 10 minutes in 3% hydrogen peroxide in PBS.
Sections were blocked by incubation with 4% BSA in PBS
and were then incubated for one hour at room temperature
with the primary antibodies. Biotin-conjugated anti-mouse sec-
ondary antibodies (Vector, Burlingame, CA, USA) were used
at a dilution of 1:250. They were incubated with the sections
for one hour at room temperature. The sections were then
incubated with streptavidin peroxidase for 30 minutes and
antibody binding was detected with the AEC staining kit
(Sigma, Lyon, France), the antigen-expressing cells being
stained brown. The number of CD68-positive cells per unit
area of inflammation was determined with commercial image
analysis software (Axiovision 4.7, Zeiss, Le Pecq, France).
Results are expressed as the number of cells per cm2 of inflam-
mation.
Dual-energy X-ray absortiometry and micro-CT analysis
Dual-energy X-ray absortiometry (DXA) was performed at the
end of the experiment, on intact animals, using a LUNAR Prod-
igy Advance densitometer (General Electric, Madison, WI,
USA) calibrated for small animals. Each rat was placed in a
prone position. Several measurements were taken: total body
weight (with % of fat mass); bone mineral content and bone
mineral density (BMD) of the femurs and lumbar spine of each
treated rat. Architectural parameters were analyzed by high-
resolution X-ray micro-CT, using the SkyScan-1072 (SkyS-
can, Aartselaar, Belgium) system for small-animal imaging.
Each tibia was scanned parallel to its longitudinal axis (60 kV,
148 μA). A core of 200 slides, each 11 μm thick (7 mm long)
was used for bone morphometry evaluations with SkyScan
CtAn software. The following factors were measured: total vol-
ume, bone volume (BV) and the BV/tissue volume (TV) ratio.
Trabecular BV and cortical BV were evaluated separately and
the ratio of these two volumes was calculated. Trabecular
bone thickness, trabecular number and separation were meas-
ured with a semi-automatic morphing procedure, from total
BV. Cortical thickness was evaluated in the middle of the
image and was assessed three times, on five separate slides.
Statistical analysis
All results are expressed as means +/- standard error of the
mean. Mann-Whitney U tests were used to compare groupArthritis Research & Therapy    Vol 11 No 6    Le Goff et al.
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mean values, in GraphPad Prism version 5 software (Graph-
PaD Software, San Diego, CA, USA). P values less than 0.05
were considered significant.
Results
Effect of MTX and ZA on the collagen-induced arthritis 
disease course
We first addressed the effects of MTX and ZA, used alone or
in combination, on the clinical course of arthritis in rats. From
day 20 to the end of the experiment, MTX treatment resulted
in an arthritis score significantly lower than those for the con-
trol and ZA groups (Figure 1a). When used alone, ZA had a
slight, but non-significant, pro-inflammatory effect, resulting in
a higher arthritis score than for the control group. The combi-
nation of MTX and ZA also attenuated the increase in total
arthritis score, but to a lesser extent than MTX alone. At the
end of the experiment, paw thickness was significantly lower
only in the MTX group (12.6 mm versus 15.5 mm in the control
group (P < 0.05); Figure 1c). The most severe exacerbations
were detected in rats treated with ZA (paw thickness of 16.2
mm). Rats treated with ZA + MTX had slightly thinner paws
(14 mm), but the difference in paw thickness between these
rats and those of the control group was not statistically signif-
icant. Body weight was measured at each clinical evaluation.
After arthritis induction, the body weight reached a plateau
from day 15 in all groups assessed (Figure 1b).
Radiological examination
The effects of treatments on local inflammation and bone ero-
sion were assessed by plain X rays of the hind paws at the end
of the experiment, with the measurement of soft-tissue swell-
ing and the degree of bone erosion. ZA treatment, alone or in
combination with MTX, significantly decreased erosion score
(1.85 ± -0.8 (P < 0.05), 1.45 ± -0.9 (P < 0.05), respectively,
versus 4.4 ± -1.5 for the control group; Figure 2e). MTX also
decreased the number of erosions, but to a lesser extent than
ZA (3 ± -1, P = not significant versus control). Conversely,
MTX decreased the soft-tissue swelling score, whereas ZA
did not (3 ± -0.7 versus 5.1 ± -0.7). Treatment with a combi-
nation of MTX and ZA decreased inflammation, but inflamma-
tion levels remained slightly higher than with MTX alone (3.4 ±
-0.6). Inflammation and erosion were clearly dissociated in the
ZA-treated group, whereas these two effects were coupled in
the MTX and control groups.
Figure 1
Clinical course of collagen-induced arthritis Clinical course of collagen-induced arthritis. (a) Arthritis score was evaluated at day 0 and day 14 (first and second collagen injections) and then 
every three days after disease onset (days 17, 20, 24 and 27). Methotrexate (MTX) treatment resulted in a significantly lower arthritis score than 
recorded for the control or zoledronic acid (ZA) groups. Arthritis score was also decreased by ZA + MTX, but the difference with the control group 
was not statistically significant. ZA had a slight pro-inflammatory effect, whether used alone or in combination with MTX. (b) Body weight (g) meas-
ured at each clinical evaluation. After arthritis induction, the body weight reached a plateau from day 15 with no significant difference between all 
groups assessed. (c) Paw swelling in rats was assessed by caliper measurement at termination according to the treatments. MTX resulted in a sig-
nificantly greater reduction in paw thickness at the end of the experiment. No such effect was observed with ZA or ZA + MTX. *P < 0.05 versus CT 
group; +P < 0.05 versus ZA group.Available online http://arthritis-research.com/content/11/6/R185
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Effects of treatments on inflammation and CD68+ cells
To address the effect of ZA and MTX on synovial inflammation
we next performed a histological analysis of the joints (Figure
3). Histological inflammation scores were significantly lower in
MTX-treated rats than in the control and ZA-treated groups
(1.4 ± -0.2 versus 2.3 ± -0.14 (P = 0.005) and 2.2 ± -0.15 (P
= 0.01), respectively). We found no difference in paw inflam-
mation between the ZA and control groups. Treatment with a
combination of MTX and ZA significantly decreased the inflam-
mation score, but was less effective than MTX alone (1.6 ± -
0.2, P = 0.04 versus control).
We then investigated the effect of treatment on CD68+ cells,
which arise from the monocytic lineage and include potential
Figure 2
Representative plain radiographs of the hind paws obtained at the end of the experiment Representative plain radiographs of the hind paws obtained at the end of the experiment. The (a) control, (b) methotrexate (MTX), (c) zoledronic 
acid (ZA), and (d) ZA + MTX groups are shown. Severe loss of subchondral bone was seen in the control group, with multiple areas of erosion, 
whereas lower levels of destruction were observed in MTX-treated rats. ZA completely prevented bone destruction. (e) Soft-tissue swelling and ero-
sion radiographic score for the ankle and tarsus joints. ZA alone or in combination with MTX significantly decreased the erosion score, but had a pro-
inflammatory effect, increasing soft-tissue swelling. MTX also decreased the number of areas of erosion and decreased the soft-tissue swelling. *P < 
0.05 versus computed tomography (CT) group.
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Representative histological profiles of rat ankle joints at the end of the experiment Representative histological profiles of rat ankle joints at the end of the experiment. The (a) control, (b) methotrexate (MTX), (c) zoledronic acid (ZA), 
and (d) ZA + MTX groups are shown (×10). Immunohistochemical staining, with CD68+ cells stained brown. (e) Histological inflammation score. 
MTX, whether used alone or in combination with ZA, significantly decreased the inflammation score, as shown by comparisons with the control 
group. (f) Number of CD68+ cells per unit area of inflammation. MTX, whether used alone or in combination with ZA, resulted in the presence of sig-
nificantly fewer CD68+ cells than observed in the control and ZA groups. *P < 0.05 versus computed tomography (CT) group; **P < 0.005 versus 
CT group; ++P < 0.005 versus ZA group.
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osteoclast precursors. We considered only cells present in
the inflammatory infiltrate, ignoring those on the surface of the
bone, to avoid counting mature osteoclasts. MTX treatment,
alone or in combination with ZA, resulted in the presence of
significantly fewer CD68+ cells/cm2 in the inflammatory infil-
trate (Figure 3f) than were observed in the control group
(12.78 ± -3 (P = 0.03) and 13.3 ± 1.4 (P = 0.02), respec-
tively, versus 23.1 ± -2.5) or the ZA group (23.8 ± -2.5; P =
0.04 and P = 0.01, respectively). ZA had no effect on the
number of CD68+ cells.
Effects of treatments on histological erosion score and 
osteoclast number
Histological analysis was carried out to confirm the effects of
treatments on bone erosion observed on plain X-rays. Bone
erosion, as assessed by a semi-quantitative score, was
strongly inhibited in rats treated with ZA (1.2 ± -0.09 versus
2.5 ± -0.1 for the control group (P < 0.0001); Figure 4e). MTX
also reduced significantly the erosion score compared with
control, although this score remained higher than that for ZA
(1.8 ± -0.3; P = 0.03). The combination of ZA and MTX was
significantly more effective in the prevention of erosion than
MTX alone (1.8 ± -0.3 versus 1.01 ± -0.07; P  = 0.01),
whereas there was no difference between the ZA + MTX and
ZA groups (P = 0.1).
To assess the effect of ZA and MTX on the number of osteo-
clasts, joint sections were stained with TRAP. Only TRAP-pos-
itive multinucleated cells located at the bone surface within the
bone erosions were considered to be osteoclasts. ZA,
whether used alone or in combination with MTX, strongly
decreased the number of osteoclasts in the areas of erosion.
ZA treatment (alone or together with MTX) resulted in signifi-
cantly fewer osteoclasts in these areas than observed in the
control group and the group of animals treated with MTX alone
(12 ± -1.8 and 8.2 ± -1.4 versus 33.9 ± -4 and 21.1 ± -3
respectively; Figure 4f). However, a significant decrease of
osteoclast number was also present in MTX-treated group
compared with the CT group (P = 0.04).
Effects of treatments on bone density and micro-CT 
parameters
We assessed the effects of treatments on BMD, by carrying
out DXA on the right femurs and lumbar spine of rats at the
end of the experiment. The BMD of the femur was significantly
higher in rats treated with ZA or with ZA + MX than in the rats
of the control group (+16%, P = 0.01 and +18%, P = 0.005,
respectively; Figure 5). BMD was similar in the MTX and con-
trol groups (0.19 ± -0.006 versus 0.18 ± -0.01 g/cm2; P =
0.6). No difference in total body weight or percentage fat mass
was found between the four groups (data not shown).
Figure 4
Representative TRAP staining profiles Representative TRAP staining profiles. The (a) control, (b) zoledronic acid (ZA), (c) methotrexate (MTX), and (d) ZA + MTX groups are shown 
(×40). (e) Erosion score. Bone erosion was strongly inhibited in the ZA group. MTX also significantly reduced bone erosion, although to a lesser 
extent than ZA. (f) Number of osteoclasts (multinucleated tartrate resistant acid phosphatase (TRAP) positive cells) at the bone/synovium interface 
in the eroded joint of the tibiotarsal and intertarsal joints. ZA, used alone or in combination with MTX, strongly decreased the number of TRAP-posi-
tive cells. MTX also decreased the number of TRAP+ cells in the eroded joint. *P < 0.05 versus computed tomography (CT) group; **P < 0.005 ver-
sus CT group; +P < 0.05 versus MTX group.
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The effects of the treatments on systemic bone loss were
assessed by micro-CT evaluation of the proximal end of the left
tibia with a quantitative histomorphometric imaging method
(Figure 6). ZA treatment alone or in association with MTX sig-
nificantly increased the ratio of BV/TV (58.7 ± -12 and 53.9 ±
-3%) over that in the control (32.5 ± -4%; P = 0.03 and P =
0.01, respectively), whereas treatment with MTX alone did not
(36.7 ± -3, P = 0.4). Cortical thickness was also increased by
ZA treatment (0.47 mm versus 0.38 mm in the control group,
P < 0.05), but not by MTX (0.39 mm). Trabecular and cortical
Figure 5
Bone density measured with a densitometer suitable for use with small animals Bone density measured with a densitometer suitable for use with small animals. Zoledronic acid (ZA) significantly increased the bone density of the 
femur and spine in rats. We found no difference between the control and methotrexate (MTX) groups. Treatment with a combination of MTX + ZA 
was as effective as treatment with ZA alone. Values are the mean ± standard deviation. *P < 0.05 versus computed tomography (CT) group; +P < 
0.05 versus MTX group.
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Figure 6
Micro-CT analysis Micro-CT analysis. (a) Representative micro-computed tomography (CT) image of the distal tibia for each rat group. (b) Histomorphometric analysis 
of the distal tibia for the various treatment groups, showing a significant increase in bone volume (BV)/tissue volume (TV) ratio, cortical thickness, 
trabecular and cortical bone volume and trabecular thickness in rats treated with zoledronic acid (ZA). Methotrexate (MTX) had no effect on histo-
morphometric parameters. Values are the mean ± standard deviation. **P < 0.005 versus CT group; ++P < 0.005 versus MTX group.
Control MTX ZA ZA+MTX
Bone volume/Tissu volume (%) 32.5 (+/-8) 36.7 (+/-6) 58.7 (+/-12)**++ 53.9 (+/-8)**++
Cortical thickness (mm) 0.38 0.39 0.47**++ 0.45**++
Cortical bone volume (mm3) 13.58 13.75 18.80**++ 19.74**++
Trabecular bone volume (mm3) 7.33 8.83 12.15**++ 12.92**++
Cortical /Trabecular bone volume 1.85 1.56 1.55 1.53
Pourcentage of Trabecular bone 36.7 38.7 36.7 40.6
Trabecular thickness (mm) 0.25 0.28 0.44**++ 0.46**++
Trabecular number 1.5 1.4 1.16 1.2
Trabecular separation (mm) 0.41 0.45 0.41 0.32
(a)
(b)
CT MTX ZA ZA+MTXArthritis Research & Therapy    Vol 11 No 6    Le Goff et al.
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bone volumes were increased by ZA, with no change in the
cortical/trabecular volume ratio. Trabecular thickness was sig-
nificantly greater in the groups treated with ZA or ZA + MTX
than in the control group, whereas there was no significant dif-
ference between the group treated with MTX and the control
group.
Discussion
Bone erosions and generalized bone loss are among the most
serious features of RA, leading to joint deformation, fractures,
and severe disability. New evidence has confirmed that osteo-
clasts are key mediators of these two sorts of bone loss in RA.
Traditional disease-modifying antirheumatic drugs (DMARDs)
and biological treatments are capable of controling joint
inflammation and bone erosions in most RA patients. How-
ever, some patients experience worsening structural joint dam-
age despite apparently good control of disease activity. In
such patients, a combination of MTX (and/or biological
agents) with anti-resorptive drugs directly targeting patho-
genic osteoclasts, might be a practical solution. We investi-
gated this possibility, by comparing the clinical and structural
efficacy of MTX and ZA, alone or as a combination, in a rat CIA
model.
Our study findings confirm that MTX and ZA are efficient in the
prevention of arthritic bone destruction. Indeed, both treat-
ments significantly decreased radiographic and histological
erosion scores in colagen-induced arthritis, with ZA the more
effective of the two. In our experiments, ZA decreased the
number of osteoclasts in the ankle, where a clear dissociation
between inflammation and destruction was observed. ZA
strongly and selectively down-regulated the number of TRAP+
cells but had no effect on the inflammatory infiltrate. This dis-
sociation between bone protection and inflammation has been
described before and indicates a direct effect of ZA on osteo-
clast numbers [12,13]. Osteoprotegerin, an inhibitor of osteo-
clastogenesis, also decreases the number of osteoclasts and
gave similar results [5].
Despite experimental demonstrations of the efficacy of ZA for
preventing bone erosion, the use of bisphosphonates in daily
practice for the treatment of RA patients remains controversial.
A single-center, proof-of-concept study of 39 patients receiv-
ing MTX by Jarrett and colleagues showed that addition of ZA
to the treatment regimen decreased magnetic resonance
imaging erosion scores by 61% at six months compared with
MTX alone [14]. However, less potent bisphosphonates, such
as clonodronate or pamidronate, prevent bone erosion only if
used at high doses [23-25]. ZA is a third-generation bisphos-
phonate with an inhibitory effect on bone resorptive activity
that are 100-fold to 10,000-fold stronger than those of the
second and first generation. Moreover, a dose of 20 μg/kg is
sufficient to prevent bone loss in ovariectomized rats [26]. The
high dose of ZA used in our study and its powerful inhibitory
effect on osteoclast-mediated bone resorption may account
for the dramatic decrease in bone erosion observed. These
results must be tempered by the consideration that ZA may
have a proinflammatory effect and decrease the effectiveness
of MTX. Indeed, we observed that ZA used alone or in combi-
nation with MTX had a slight but not significant pro-inflamma-
tory effect with an increased arthritis score and paws
thickness at the end of the experiment. However, bisphospho-
nates, such as alendronate or clonodronate, used in animal
models of arthritis, demonstrated an anti-inflammatory effect
[27]. These discrepancies are probably related to the differ-
ence of dose and type of bisphosphonate used. The potential
proinflammatory effect and the risk of jaw osteonecrosis asso-
ciated with the use of a high dose of bisphosphonate indicate
that low dose of ZA would probably be the best option for RA
patients.
The mechanisms responsible for structural joint protection by
MTX are unclear and probably multifactorial. MTX has a pow-
erful anti-inflammatory effect in vivo and inhibits human syno-
vial fibroblast RANK-L production and osteoclastogenesis in a
dose-dependent manner [18]. In vitro, MTX also abolishes the
IL-6 synthesis stimulated by pro-inflammatory cytokines such
as IL-17 and TNF-α in osteoblasts [28]. Furthermore, MTX
promotes adenosine release in vivo and in vitro and adenosine
strongly inhibits the monocyte fraction, which contains osteo-
clast precursors [29,30]. Thus, multiple mechanisms may
explain the inhibitory effects of MTX on inflammatory bone
destruction. In adjuvant arthritis, MTX increases the number of
osteoclasts and pit formation in bone marrow cultures from
non-arthritic rats, but has no effect on bone mass [31]. In
arthritic rats, MTX attenuates arthritis and restored the
decreased osteogenic activity o f  b o n e  m a r r o w  c e l l s ,  a n d
reduced their increased bone resorptive activity to normal lev-
els [31]. Similarly, and consistent with the inhibitory effects of
MTX on monocytes, our study provides evidence that MTX
reduces the number of CD68+ cells in the inflammatory infil-
trate. Interestingly it also decreases TRAP+ (osteoclast) cell
numbers in rats with collagen-induced arthritis. However, the
precise effect of MTX on osteoclast precursors population
needs to be clarified.
The skeletal effects of MTX are well known. High dosage of
MTX has negative effects on bone mass in patients treated for
malignancies [32], and the prolonged administration of low
doses of MTX in rats causes significant osteopenia due to the
inhibition of osteoblast activity and the stimulation of osteo-
clast recruitment, resulting in a net increase in bone resorption
[33,34]. The bone disease induced by high doses of MTX is
characterized by stress fractures, diffuse bone pain and oste-
oporosis [35]. However, possible bone toxicity of long-term,
low-dose MTX treatment in humans remains a matter of
debate and is difficult to demonstrate in cross-sectional
[36,37] or longitudinal studies [38]. In our study, we found no
difference between rats with collagen-induced arthritis given
short-term MTX treatment and control rats in terms of BMDAvailable online http://arthritis-research.com/content/11/6/R185
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and histomorphometric analysis. Indeed, in our experiments,
ZA increased BMD and improved all histomorphometric
parameters. These results are consistent with those of Spa-
daro and colleagues, who found that alendronate prevented
bone loss induced by high-doses of MTX treatment in rats
[39]. Other bisphosphonates, such as alendronate, have also
been shown to be effective in the prevention of systemic bone
loss associated with RA during treatment with MTX [40] or
corticosteroids [11]. Our experimental results suggest that
treatment with a combination of ZA and MTX would have ben-
eficial effects in many RA patients, by decreasing joint erosion
and increasing bone mineral density.
Conclusions
In summary, our study demonstrates that a combination of
MTX and ZA prevented both bone erosion and systemic bone
mass loss in the collagen-induced arthritis model of RA. In our
study, ZA was more effective than MTX for preventing struc-
tural damage. MTX and ZA both decreased the number of
osteoclasts in the eroded joint, but seemed to prevent bone
erosion in different ways. ZA is known to inhibit osteoclast for-
mation, function and survival. It therefore probably acts on
mature osteoclasts, without reducing the number of osteoclast
precursors. Our data suggest that MTX may also inhibit oste-
oclastogenesis. We observed that it decreases the number of
CD68+ cells in the synovium. Further studies will be required
to elucidate the precise effects of MTX on RANK+ precursor
cells within the CD68+ monocyte fraction. These different
mechanisms of action provide a rationale for combining these
two commonly used drugs to improve the prevention of struc-
tural joint damage in RA. Randomized clinical trials comparing
MTX used alone and MTX used in combination with ZA should
be carried out to establish a rational treatment strategy for RA.
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